Matthew Wright

Discovery of 1-[3-(Aminomethyl)phenyl]-<i>N</i>-[3-fluoro-2‘-(methylsulfonyl)- [1,1‘-biphenyl]-4-yl]-3-(trifluoromethyl)-1<i>H</i>-pyrazole-5-carboxamide (DPC423), a Highly Potent, Selective, and Orally Bioavailable Inhibitor of Blood Coagulation Factor Xa

Donald Pinto, Michael J. Orwat, Shuaige Wang et al. · Journal of Medicinal Chemistry · 2001 · 172 citations · Full text

Medicine, Pharmacology, Drug Discovery +11

Structure-Based Design of Novel Guanidine/Benzamidine Mimics:  Potent and Orally Bioavailable Factor Xa Inhibitors as Novel Anticoagulants

Patrick Y. S. Lam, Charles G. Clark, Renhua Li et al. · Journal of Medicinal Chemistry · 2003 · 96 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +15

Design and Synthesis of Isoxazoline Derivatives as Factor Xa Inhibitors. 2

Mimi L. Quan, Christopher D. Ellis, Ann Y. Liauw et al. · Journal of Medicinal Chemistry · 1999 · 77 citations

Pharmacy, Medicinal Chemistry, Pharmacology +10

Discovery of 1-(2-Aminomethylphenyl)-3-trifluoromethyl-<i>N</i>- [3-fluoro-2‘-(aminosulfonyl)[1,1‘-biphenyl)]-4-yl]-1<i>H</i>-pyrazole-5-carboxyamide (DPC602), a Potent, Selective, and Orally Bioavailable Factor Xa Inhibitor

James R. Pruitt, Donald Pinto, Robert A. Galemmo et al. · Journal of Medicinal Chemistry · 2003 · 75 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +15

Hepatic metabolism and biliary excretion of Taxol in rats and humans.

Bernard Monsarrat, Paul Alvinerie, Matthew Wright et al. · PubMed · 1993 · 73 citations

Pharmacy, Pharmacokinetics, Pharmacology +16